Startups
As a professional data & media company, we are dedicated to providing important healthcare knowledge
Overview
Location
China, Beijing
Employees
51-200
Founded date
2013
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 13, 2020 | Out to pioneer gene editing in China, EdiGene bags $67M to begin clinical testing for β-thalassemia therapy, universal CAR-T | A gene editing player hailing from Beijing has clinched $67 million to steer two of its lead candidates into the clinic — and to prove itself as a CRISPR pioneer in China. Dong Wei EdiGene gathered the Series B from a slate ... |
| Mar 9, 2020 | Chinese biotech bags $50M+ for I/O, autoimmune work, starting with ALK5 inhibitor | For the last decade or so, many of the more eye-catching Chinese biotech startups share two defining attributes: seasoned execs trained at multinational biopharma companies and a mission to bridge the gap between Western ... |
| Feb 18, 2020 | China approves flu drug being touted as a potential coronavirus treatment amid a rush of clinical studies | One of the three drugs that China’s Ministry of Science and Technology has tapped as potential COVID-19 treatments to watch has notched its first Chinese OK — for the flu. While there’s no proof yet that fapilavir, or favipiravir... |
| May 29, 2019 | Ready to harvest its PD-L1, Alphamab reloads with $60M to nurture the bispecific patch | Alphamab’s $100 million Series A last November for the oncology unit marked its first venture round in almost 10 years of existence. As it turned out, it was also a signal that founder and CEO Ting Xu was ready to bring in th... |
| Mar 21, 2019 | Shanghai-based cancer drugmaker Abbisko lines up $42M B round as it makes a leap for the clinic | Qiming Ventures is leading a B round for Abbisko Therapeutics, more than doubling the Shanghai-based biotech’s previous haul as it hustles a pair of homegrown cancer drugs toward an IND. Yaochang Xu Abbisko Therapeutics r... |
| Oct 29, 2018 | A photo log of my week in Shanghai, hosting the first annual US-China Biopharma Innovation and Investment Summit | I’ve returned from a week in Shanghai after hosting our first BIIS conference in China. It was extraordinarily successful from my standpoint as the chief executive here at Endpoints News. (Yes, we’ll be returning even... |
| Mar 26, 2018 | China's biotech pipeline is brimming with PD-1/L1 checkpoints. Are they really needed? | The big US and European markets aren’t the only place where PD-1/L1 checkpoint drugs are crowding in. Beginning later this year, the data analytics firm PharmCube reports, Keytruda and Opdivo should both be green lighted ... |
Reviews 0
FAQ about PharmCube
When was PharmCube founded?
PharmCube was founded in 2013.
What has the press written about PharmCube?
Parsers VC has collected 8 articles mentioning PharmCube, among them “Out to pioneer gene editing in China, EdiGene bags $67M to begin clinical testing for β-thalassemia therapy, universal CAR-T” (Oct 13, 2020) and “Chinese biotech bags $50M+ for I/O, autoimmune work, starting with ALK5 inhibitor” (Mar 9, 2020).
Is PharmCube still active?
PharmCube is probably closed: its latest activity on Parsers VC dates from May 31, 2023.